Kana Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kana Sasaki has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hironori Waki
Department of Metabolism and Endocrinology Akita University Graduate School of Medicine Akita Japan
2 shared publications Sayaka Ando
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications- Shogo Iwamura
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications - Shunsuke Kato
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications - Takehiro Sato
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications Tatsunori Shimizu
Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (5) , 138
Identifying Mild Cognitive Impairment from Routinely Collected Physical, Functional and Psychosocial Measures in Community-Dwelling Older Adults: A Comparative Machine-Learning and Regression Modelling Study in the Northern Japanese ORANGE Registry
Background: Community health check-ups routinely collect non-cognitive data. Whether these support mild cognitive impairment (MCI) triage, and whether machine learning outperforms regression, is unclear. Methods: Cross-sectional analysis of 2650 community-dwelling adults aged ≥ 65 in Akita, Japan (2018–2025). MCI was defined by the NCGG-FAT (1.5 SD, age/education-adjusted norms). Thirty-four pre-specified non-cognitive predictors were modelled using tree ensembles, penalised regression, other machine-learning families and simple reference scores, with stratified 70/30 splitting, DeLong tests, 100 repeated splits, training-derived thresholds, calibration metrics and decision-curve analysis. Results: MCI prevalence was 28.6%. Random forest discriminated best (ROC AUC 0.722, 95% CI 0.681–0.761; PR-AUC 0.542) and was well calibrated (slope 1.048; intercept −0.024), but its advantage over LASSO regression was marginal (ΔAUC +0.031, p = 0.044) and absent versus gradient boosting (p = 0.059). All multivariable models greatly outperformed the Kihon Checklist (AUC 0.550, p < 0.001). Neither operating point was deployable: at 0.5, sensitivity was 0.269 (166/227 cases missed); at the training-derived Youden threshold (0.321), sensitivity was 0.604, specificity 0.699, and PPV 0.445. Net benefit exceeded assess-all/assess-none between threshold probabilities 0.15–0.60. Conclusions: Routine non-cognitive data support moderate, well-calibrated MCI discrimination, but machine learning added little over regression. This is an exploratory triage aid requiring external validation.
- 1 October 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (5) , 138
Open AccessIdentifying Mild Cognitive Impairment from Routinely Collected Physical, Functional and Psychosocial Measures in Community-Dwelling Older Adults: A Comparative Machine-Learning and Regression Modelling Study in the Northern Japanese ORANGE Registry
Background: Community health check-ups routinely collect non-cognitive data. Whether these support mild cognitive impairment (MCI) triage, and whether machine learning outperforms regression, is unclear. Methods: Cross-sectional analysis of 2650 community-dwelling adults aged ≥ 65 in Akita, Japan (2018–2025). MCI was defined by the NCGG-FAT (1.5 SD, age/education-adjusted norms). Thirty-four pre-specified non-cognitive predictors were modelled using tree ensembles, penalised regression, other machine-learning families and simple reference scores, with stratified 70/30 splitting, DeLong tests, 100 repeated splits, training-derived thresholds, calibration metrics and decision-curve analysis. Results: MCI prevalence was 28.6%. Random forest discriminated best (ROC AUC 0.722, 95% CI 0.681–0.761; PR-AUC 0.542) and was well calibrated (slope 1.048; intercept −0.024), but its advantage over LASSO regression was marginal (ΔAUC +0.031, p = 0.044) and absent versus gradient boosting (p = 0.059). All multivariable models greatly outperformed the Kihon Checklist (AUC 0.550, p < 0.001). Neither operating point was deployable: at 0.5, sensitivity was 0.269 (166/227 cases missed); at the training-derived Youden threshold (0.321), sensitivity was 0.604, specificity 0.699, and PPV 0.445. Net benefit exceeded assess-all/assess-none between threshold probabilities 0.15–0.60. Conclusions: Routine non-cognitive data support moderate, well-calibrated MCI discrimination, but machine learning added little over regression. This is an exploratory triage aid requiring external validation.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0235
Metreleptin improves glucose metabolism and hepatic steatosis in a patient with Werner syndrome and partial lipodystrophy: a case report with review of literature
Werner syndrome (WS) is a rare autosomal recessive progeroid disorder caused by mutations in the WRN gene and is characterized by distinctive physical features and metabolic complications, including insulin resistance, diabetes, hypertriglyceridemia, and hepatic steatosis. Although lipodystrophy is a recognized component of WS, clinical reports of metreleptin use in this setting remain very limited. We report the case of a 38-year-old woman with WS complicated by partial lipodystrophy, diabetes with suboptimal glycemic levels, hypertriglyceridemia and severe hepatic steatosis. She presented with distal limb lipoatrophy, a bird-like facial appearance, premature hair graying, and cataracts. Genetic testing identified two pathogenic WRN variants (c.1105C>T and c.3446del) resulting in premature protein termination, confirming the diagnosis. At baseline, hemoglobin A1c (HbA1c) was 8.6% despite insulin and oral hypoglycemic agents, and imaging demonstrated hepatomegaly with marked steatosis. Metreleptin therapy was initiated and titrated. Over 26 weeks, HbA1c improved to 7.4% and the visceral-to-subcutaneous fat ratio decreased, accompanied by reduction in liver transaminases, cholestatic enzymes, and imaging-based indices of hepatic steatosis, liver stiffness, and liver volume. To date, only three cases of WS treated with metreleptin, including ours, have been reported. While glycemic improvement is consistent with prior reports, our case additionally demonstrated improvements in hepatic steatosis across biochemical, and imaging parameters. These findings suggest that metreleptin may improve both glucose metabolism and hepatic steatosis in WS-associated lipodystrophy. Further accumulation of cases is essential to clarify its role in the management of WS.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0235
Open AccessMetreleptin improves glucose metabolism and hepatic steatosis in a patient with Werner syndrome and partial lipodystrophy: a case report with review of literature
Werner syndrome (WS) is a rare autosomal recessive progeroid disorder caused by mutations in the WRN gene and is characterized by distinctive physical features and metabolic complications, including insulin resistance, diabetes, hypertriglyceridemia, and hepatic steatosis. Although lipodystrophy is a recognized component of WS, clinical reports of metreleptin use in this setting remain very limited. We report the case of a 38-year-old woman with WS complicated by partial lipodystrophy, diabetes with suboptimal glycemic levels, hypertriglyceridemia and severe hepatic steatosis. She presented with distal limb lipoatrophy, a bird-like facial appearance, premature hair graying, and cataracts. Genetic testing identified two pathogenic WRN variants (c.1105C>T and c.3446del) resulting in premature protein termination, confirming the diagnosis. At baseline, hemoglobin A1c (HbA1c) was 8.6% despite insulin and oral hypoglycemic agents, and imaging demonstrated hepatomegaly with marked steatosis. Metreleptin therapy was initiated and titrated. Over 26 weeks, HbA1c improved to 7.4% and the visceral-to-subcutaneous fat ratio decreased, accompanied by reduction in liver transaminases, cholestatic enzymes, and imaging-based indices of hepatic steatosis, liver stiffness, and liver volume. To date, only three cases of WS treated with metreleptin, including ours, have been reported. While glycemic improvement is consistent with prior reports, our case additionally demonstrated improvements in hepatic steatosis across biochemical, and imaging parameters. These findings suggest that metreleptin may improve both glucose metabolism and hepatic steatosis in WS-associated lipodystrophy. Further accumulation of cases is essential to clarify its role in the management of WS.
- Open Access
- 22 September 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112913
Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study
- 22 September 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 229, 112913
Open AccessImpact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study